Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001389932-24-000022
Filing Date
2024-11-14
Accepted
2024-11-14 14:35:48
Documents
1
Group Members
NATHAN FISCHEL, FARIBA GHODSIAN

Document Format Files

Seq Description Document Type Size
1 dafna13grgls3Q2024.txt SC 13G/A 9988
  Complete submission text file 0001389932-24-000022.txt   11617
Mailing Address 10990 WILSHIRE BOULEVARD SUITE 1400 LOS ANGELES CA 90024
Business Address 10990 WILSHIRE BOULEVARD SUITE 1400 LOS ANGELES CA 90024 (310) 954-3200
DAFNA Capital Management LLC (Filed by) CIK: 0001389933 (see all company filings)

EIN.: 364334068
Type: SC 13G/A

Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Subject) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-87002 | Film No.: 241460497
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)